<DOC>
	<DOCNO>NCT02590055</DOCNO>
	<brief_summary>It 's phase 2 , single arm study gemcitabine docetaxel combination patient carcinoma unknown primary .</brief_summary>
	<brief_title>Phase 2 Study Gemcitabine Docetaxel Combination Chemotherapy Patients With Carcinoma Unknown Primary</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1. age &gt; =20 2. pathologically confirm patient carcinoma unknown primary 3. unfavorable type CUP 4 . ECOG PS 02 5. 1 evaluable lesion 6. life expectancy &gt; 12 week 7. prior history chemotherapy 8. 2 week surgery radiotherapy 9. proper organ function 10. write informed consent 1. favorable group CUP squamous cell carcinoma cervical inguinal LN woman axillary LN metastasis woman peritoneal carcinomatosis welldifferentiated neuroendocrine tumor poorlydifferentiated tumor midline tumor elevate human HCG/AFP men adenocarcinoma elevate PSA 2. severe , unstable heart disease 3. uncontrolled systemic disease ( DM , HTN , hypothyroidism , infection ... ) 4. pregnant feed woman 5. current CNS tumor ( except total removal WBRT/GKS do )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>